Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function

被引:19
作者
Mantesso, Simone [1 ]
Geerts, Dirk [1 ]
Spanholtz, Jan [1 ]
Kucerova, Lucia [1 ]
机构
[1] Glycostem Therapeut, Res & Dev, Oss, Netherlands
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
基金
欧盟地平线“2020”;
关键词
natural killer cells; tumor; genetic engineering; transduction; transfection; chimeric antigen receptor-natural killer cells; activating receptors; inhibitory receptors; RECIPROCAL ACTIVATING INTERACTION; CHIMERIC ANTIGEN RECEPTOR; TGF-BETA RECEPTOR; NK CELLS; T-CELLS; HLA-E; PROGNOSTIC-SIGNIFICANCE; SURFACE-MOLECULE; STEM-CELLS; PVR CD155;
D O I
10.3389/fimmu.2020.607131
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural Killer (NK) cells are unique immune cells capable of efficient killing of infected and transformed cells. Indeed, NK cell-based therapies induced response against hematological malignancies in the absence of adverse toxicity in clinical trials. Nevertheless, adoptive NK cell therapies are reported to have exhibited poor outcome against many solid tumors. This can be mainly attributed to limited infiltration of NK cells into solid tumors, downregulation of target antigens on the tumor cells, or suppression by the chemokines and secreted factors present within the tumor microenvironment. Several methods for genetic engineering of NK cells were established and consistently improved over the last decade, leading to the generation of novel NK cell products with enhanced anti-tumor activity and improved tumor homing. New generations of engineered NK cells are developed to better target refractory tumors and/or to overcome inhibitory tumor microenvironment. This review summarizes recent improvements in approaches to NK cell genetic engineering and strategies implemented to enhance NK cell effector functions.
引用
收藏
页数:12
相关论文
共 106 条
  • [31] CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
    Grzywacz, B.
    Kataria, N.
    Verneris, M. R.
    [J]. LEUKEMIA, 2007, 21 (02) : 356 - 359
  • [32] Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines
    Halama, Niels
    Braun, Monika
    Kahlert, Christoph
    Spille, Anna
    Quack, Christian
    Rahbari, Nuh
    Koch, Moritz
    Weitz, Juergen
    Kloor, Matthias
    Zoernig, Inka
    Schirmacher, Peter
    Brand, Karsten
    Grabe, Niels
    Falk, Christine S.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (04) : 678 - 689
  • [33] HANNA N, 1981, J IMMUNOL, V127, P1754
  • [34] Myeloid Derived Suppressor Cells Inhibit Natural Killer Cells in Patients with Hepatocellular Carcinoma via the NKp30 Receptor
    Hoechst, Bastian
    Voigtlaender, Torsten
    Ormandy, Lars
    Gamrekelashvili, Jaba
    Zhao, Fei
    Wedemeyer, Heiner
    Lehner, Frank
    Manns, Michael P.
    Greten, Tim F.
    Korangy, Firouzeh
    [J]. HEPATOLOGY, 2009, 50 (03) : 799 - 807
  • [35] Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4
    Holt, Dawn
    Ma, Xinrong
    Kundu, Namita
    Fulton, Amy
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (11) : 1577 - 1586
  • [36] Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
    Hsu, Joy
    Hodgins, Jonathan J.
    Marathe, Malvika
    Nicolai, Chris J.
    Bourgeois-Daigneault, Marie-Claude
    Trevino, Troy N.
    Azimi, Camillia S.
    Scheer, Amit K.
    Randolph, Haley E.
    Thompson, Thornton W.
    Zhang, Lily
    Iannello, Alexandre
    Mathur, Nikhita
    Jardine, Karen E.
    Kirn, Georgia A.
    Bell, John C.
    McBurney, Michael W.
    Raulet, David H.
    Ardolino, Michele
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (10) : 4654 - 4668
  • [37] Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
    Huang, Rih-Sheng
    Shih, Hsin-An
    Lai, Min-Chi
    Chang, Yao-Jen
    Lin, Steven
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [38] Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
    Imai, C
    Iwamoto, S
    Campana, D
    [J]. BLOOD, 2005, 106 (01) : 376 - 383
  • [39] Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
    Imai, K
    Matsuyama, S
    Miyake, S
    Suga, K
    Nakachi, K
    [J]. LANCET, 2000, 356 (9244) : 1795 - 1799
  • [40] Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
    Imamura, Masaru
    Shook, David
    Kamiya, Takahiro
    Shimasaki, Noriko
    Chai, Sally M. H.
    Coustan-Smith, Elaine
    Imai, Chihaya
    Campana, Dario
    [J]. BLOOD, 2014, 124 (07) : 1081 - 1088